Xia Dongjian, Zhang Zhuang, Zhao Yuanli
Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University.
Department of Neurosurgery, the First Affiliated Hospital, Jinzhou Medical University.
Biol Pharm Bull. 2018;41(11):1645-1651. doi: 10.1248/bpb.b18-00210.
Acteoside (ACT) has been shown to exert antioxidant and neuroprotective effects in neurodegenerative diseases. However, the effect of ACT on cerebral ischemia-reperfusion (I/R) injury is not yet clear. In this study, we found that ACT administration reduced infarct volume and brain edema, and improved neurological deficits, as indicated by the decreased modified neurological severity score. Administration of ACT strikingly reduced oxidative stress, accompanied by decreased levels of reactive oxygen species and malondialdehyde and increased levels of superoxide dismutase and catalase in a rat model of middle cerebral artery occlusion/reperfusion (MCAO/R). Furthermore, ACT administration reduced the number of terminal deoxynucleotidyl transferase uridine 5'-triphosphate (UTP) nick-end labeling-positive cells in the cerebral cortex of ischemic side of MCAO/R rats, accompanied by downregulation of B cell lymphoma 2 (Bcl-2) associated X protein and cleaved caspase-3 proteins and upregulation of Bcl-2 protein. Additionally, ACT treatment inhibited the protein kinase R/eukaryotic initiation factor-2α stress pathway in the brains of MCAO/R rats. Our results demonstrated that ACT attenuates oxidative stress and neuronal apoptosis in MCAO/R rats, suggesting that ACT may serve as a novel therapeutic candidate for the treatment of I/R brain injury.
毛蕊花糖苷(ACT)已被证明在神经退行性疾病中具有抗氧化和神经保护作用。然而,ACT对脑缺血再灌注(I/R)损伤的影响尚不清楚。在本研究中,我们发现给予ACT可减少梗死体积和脑水肿,并改善神经功能缺损,改良神经功能严重程度评分降低表明了这一点。在大脑中动脉闭塞/再灌注(MCAO/R)大鼠模型中,给予ACT可显著降低氧化应激,同时活性氧和丙二醛水平降低,超氧化物歧化酶和过氧化氢酶水平升高。此外,给予ACT可减少MCAO/R大鼠缺血侧大脑皮质中末端脱氧核苷酸转移酶尿苷5'-三磷酸(UTP)缺口末端标记阳性细胞的数量,同时下调B细胞淋巴瘤2(Bcl-2)相关X蛋白和裂解的半胱天冬酶-3蛋白,并上调Bcl-2蛋白。此外,ACT处理可抑制MCAO/R大鼠脑中蛋白激酶R/真核起始因子-2α应激通路。我们的结果表明,ACT可减轻MCAO/R大鼠的氧化应激和神经元凋亡,提示ACT可能作为治疗I/R脑损伤的新型候选药物。